Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group
- 23 April 2007
- journal article
- Published by Wiley in International Journal of Cancer
- Vol. 121 (5), 1138-1148
- https://doi.org/10.1002/ijc.22751
Abstract
Advanced second generation inhibitors of histone deacetylases (HDAC) are currently used in clinical development. This study aimed at comparing the pharmacological properties of selected second generation HDAC inhibitors with the hydroxamate and benzamide head group, namely SAHA, LAQ824/LBH589, CI994, MS275 and MGCD0103. In biochemical assays using recombinant HDAC1, 3, 6 and 8 isoenzymes, SAHA and LAQ824/LBH589 behave as quite unselective HDAC inhibitors. In contrast, the benzamides CI994, MS275 and MGCD0103 are more selective, potent inhibitors of at least HDAC1 and HDAC3. All HDAC inhibitors induce histone H3 hyperacetylation, correlating with inhibition of proliferation, induction of cell differentiation and apoptosis. A broad cytotoxicity is seen across cell lines from different tumor entities with LAQ824/LBH589 being the most potent agents. The apoptosis inducing activity is evident in arrested and proliferating RKO colon cancer cells with inducible, heterologous p21waf1 expression, indicative for a cell‐cycle independent mode‐of‐action. Differentiation of MDA‐MB468 breast cancer cells is induced by benzamide and hydroxamate analogs. The reversibility of drug action was evaluated by pulse treatment of A549 lung cancer cells. Whereas paclitaxel induced irreversible cell cycle alterations already after 6 hr treatment, HDAC inhibitor action was retarded and irreversible after >16 hr treatment. Interestingly, pulse treatment was equally effective as continous treatment. Finally, the efficacy of LAQ824, SAHA and MS275 in A549 nude mice xenografts was comparable to that of paclitaxel at well tolerated doses. We conclude that despite a different HDAC isoenzyme inhibition profile, hydroxamate and benzamide analogs as studied display similar cellular profiles.This publication has 43 references indexed in Scilit:
- CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivoMolecular Cancer Therapeutics, 2006
- Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or LymphomaJournal of Clinical Oncology, 2005
- Histone deacetylase HDAC8 associates with smooth muscle α‐actin and is essential for smooth muscle cell contractilityThe FASEB Journal, 2005
- Histone deacetylase inhibitors specifically kill nonproliferating tumour cellsOncogene, 2004
- Expression and functional characterization of recombinant human HDAC1 and HDAC3Life Sciences, 2004
- Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824Cancer Research, 2004
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Differential modulation of paclitaxel-mediated apoptosis by p21Waf1 and p27Kip1Oncogene, 2000
- The language of covalent histone modificationsNature, 2000
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993